MyAmyloidosisTeam

Yes, there is a promising drug currently in trials that may reverse heart damage from amyloidosis.

ALXN2220 is a depleter monoclonal antibody that has received fast-track status from the FDA. Unlike existing treatments that slow disease progression, this drug works by helping your immune system clear harmful amyloid Show Full Answer

Yes, there is a promising drug currently in trials that may reverse heart damage from amyloidosis.

ALXN2220 is a depleter monoclonal antibody that has received fast-track status from the FDA. Unlike existing treatments that slow disease progression, this drug works by helping your immune system clear harmful amyloid deposits that have already built up in the heart.

In early trials with 40 participants who had ATTR-CM (transthyretin amyloidosis with cardiomyopathy) and heart failure, ALXN2220 showed encouraging results:

* Significantly reduced markers of amyloid buildup in the heart
* Improved heart health indicators over 12 months
* No major side effects were reported

The drug is now in phase 3 trials to determine if it can help people live longer and reduce heart-related complications. This is particularly exciting because current approved treatments like tafamidis can slow the disease but can't remove proteins already deposited in the heart.

Since this was a small initial trial, more testing is needed to confirm effectiveness on a larger scale. If you're concerned about heart damage from amyloidosis, talk with your cardiologist about your current treatment options and whether participating in clinical trials might be right for you.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Fast-Tracked Amyloidosis Drug May Reverse Heart Damage